64 citations · 64 across the 1 of their papers we have counts for
4 papers
On model-based time trend adjustments in platform trials with non-concurrent controls
Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman +9
Platform trials can evaluate the efficacy of several treatments compared to a control. The number of treatments is not fixed, as arms may be added or removed as the trial progresse…
A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching
José L. Jiménez, Julia Niewczas, Alexander Bore +1
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the intention-to-treat (ITT) analysis under regulatory standards. After the tumor pr…
Modestly Weighted Logrank Tests
Dominic Magirr, Carl-Fredrik Burman
We propose a new class of weighted logrank tests (WLRT) that control the risk of concluding that a new drug is more efficacious than standard of care, when, in fact, it is uniforml…
Optimizing Trial Designs for Targeted Therapies
Thomas Ondra, Sebastian Jobjörnsson, Robert A. Beckman +4
An important objective in the development of targeted therapies is to identify the populations where the treatment under consideration has positive benefit risk balance. We conside…